Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Non-Current Deferred Tax Liability (2022 - 2023)

Zentalis Pharmaceuticals (ZNTL) has 2 years of Non-Current Deferred Tax Liability data on record, last reported at $10.3 million in Q4 2023.

  • For Q4 2023, Non-Current Deferred Tax Liability fell 31.07% year-over-year to $10.3 million; the TTM value through Dec 2023 reached $10.3 million, down 31.07%, while the annual FY2023 figure was $10.3 million, 31.07% down from the prior year.
  • Non-Current Deferred Tax Liability reached $10.3 million in Q4 2023 per ZNTL's latest filing, up from $756000.0 in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $15.0 million in Q4 2022 and bottomed at $756000.0 in Q1 2023.